Skip to main content
Journal cover image

Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.

Journal articles  - Journal Article
Huggins, J; Messina, JA; Saullo, J; Xie, J; Zhang, A; Paranjpe, I; Lu, R; Walsh, M; Mohnasky, M; Stromberg, J; Cao, F; Grover, N; Saha, M ...
Published in: Open Forum Infect Dis
July 2026

BACKGROUND: Our understanding of the epidemiology of and risk factors for postchimeric antigen receptor T-cell therapy (CART) infections is largely based on data from single-center studies with small sample sizes. METHODS: This is a multicenter, cohort study of adult patients treated with CD19 CART between 1 January 2018 and 31 August 2021. The epidemiology of infectious complications occurring within the first year after CART is described. A Fine-Gray subdistribution hazard model was built to identify risk factors for infection. Logistic regression was used to explore risk factors for early (≤90 days post-CART) versus late (>90 days post-CART) and bacterial versus viral infection. RESULTS: One hundred and thirty-one infections occurred in 97 of 311 patients (31.2%) within 1 year of CART. By infection type, the cumulative incidence of infection was 19.0% (viral), 20.9% (bacterial), and 2.3% (fungal). The majority of infections were mild or moderate in severity (86%). Clostridiodes difficile and bloodstream infections due to Gram-negative bacilli were common bacterial infections. Respiratory viral infections were the most common viral complication and fungal infections were rare. No independent predictors of infection were identified. CONCLUSIONS: Infectious complications occur in close to a third of patients post-CART but are generally mild in severity. Though we were not able to identify independent predictors of post-CART infection, a description of their clinical characteristics and epidemiology will help to optimize management of these common complications.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Open Forum Infect Dis

DOI

ISSN

2328-8957

Publication Date

July 2026

Volume

13

Issue

7

Start / End Page

ofag423

Location

United States

Related Subject Headings

  • 3207 Medical microbiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Huggins, J., Messina, J. A., Saullo, J., Xie, J., Zhang, A., Paranjpe, I., … Andermann, T. M. (2026). Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study. Open Forum Infect Dis, 13(7), ofag423. https://doi.org/10.1093/ofid/ofag423
Huggins, Jonathan, Julia A. Messina, Jennifer Saullo, Jiayi Xie, Amy Zhang, Ishan Paranjpe, Rong Lu, et al. “Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.Open Forum Infect Dis 13, no. 7 (July 2026): ofag423. https://doi.org/10.1093/ofid/ofag423.
Huggins J, Messina JA, Saullo J, Xie J, Zhang A, Paranjpe I, et al. Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study. Open Forum Infect Dis. 2026 Jul;13(7):ofag423.
Huggins, Jonathan, et al. “Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.Open Forum Infect Dis, vol. 13, no. 7, July 2026, p. ofag423. Pubmed, doi:10.1093/ofid/ofag423.
Huggins J, Messina JA, Saullo J, Xie J, Zhang A, Paranjpe I, Lu R, Walsh M, Mohnasky M, Stromberg J, Cao F, Grover N, Saha M, Darwin A, Torres N, Tam P, Schrum D, Eberwein E, Kennedy E, Kelsey CR, Choi T, McKinney M, Kang Y, Smith M, Andermann TM. Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study. Open Forum Infect Dis. 2026 Jul;13(7):ofag423.
Journal cover image

Published In

Open Forum Infect Dis

DOI

ISSN

2328-8957

Publication Date

July 2026

Volume

13

Issue

7

Start / End Page

ofag423

Location

United States

Related Subject Headings

  • 3207 Medical microbiology
  • 3202 Clinical sciences